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Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is the most frequent inborn error of metabolism,
and accounts for 90–95% of CAH cases. The affected enzyme, P450C21, is encoded by the CYP21A2 gene, located together
with a 98% nucleotide sequence identity CYP21A1P pseudogene, on chromosome 6p21.3. Even though most patients carry
CYP21A1P-derived mutations, an increasing number of novel and rare mutations in disease causing alleles were found in
the last years. In the present work, we describe five CYP21A2 novel mutations, p.R132C, p.149C, p.M283V, p.E431K and a
frameshift g.2511_2512delGG, in four non-classical and one salt wasting patients from Argentina. All novel point mutations
are located in CYP21 protein residues that are conserved throughout mammalian species, and none of them were found in
control individuals. The putative pathogenic mechanisms of the novel variants were analyzed in silico. A three-dimensional
CYP21 structure was generated by homology modeling and the protein design algorithm FoldX was used to calculate
changes in stability of CYP21A2 protein. Our analysis revealed changes in protein stability or in the surface charge of the
mutant enzymes, which could be related to the clinical manifestation found in patients.
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Introduction
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase
deficiency (OMIM 201910) accounts for 90–95% of CAH cases
[1,2]. This autosomal recessive disorder, which is the most frequent
inborn error of metabolism, has a broad spectrum of clinical forms,
ranging from severe or classical, which includes the salt-wasting
(SW) and simple virilising (SV) forms, to the mild late onset or non-
classical form of CAH(NCCAH) [1]. Poor synthesis of cortisol, with
or without aldosterone deficiency, results in chronic stimulation of
the adrenal cortex by corticotropin (ACTH). Consequently,
overproduction of some cortisol precursors are shunted into the
androgen biosynthetic pathway, causing the signs and symptoms of
androgen excess observed in this disorder. Girls with classical CAH
are typically born with ambiguous genitalia due to the exposure to
high systemic adrenal androgen levels from the 7th week of
gestation. Patients with a concurrent defect in aldosterone
biosynthesis also present life-threatening conditions which usually
appear at 1–4 weeks of age in both sexes. The moderate enzyme
deficiency that results in NCCAH is characterized by signs of
hyperandrogenism such as early pubarche, hirsutism, oligomenor-
rhea or amenorrhea, polycystic ovaries, acne, and/or infertility.
Neonatal screening programs performed since 1977 have shown
an overall incidence of 1:15000 live births for the classical form [3–
6]. A significantly higher prevalence for NCCAH (approximately
1:1000 worldwide) have been estimated, being more frequent in
certain ethnic groups such as Jews of Eastern Europe, Hispanics
and Yugoslavs [7].
The affected enzyme, P450C21, is encoded by the CYP21A2
gene.It is located onchromosome 6p21.3adjacent to a pseudogene,
CYP21A1P, with which it shares 98% nucleotide sequence identity.
Due to the high degree of identity between this gene and its
pseudogene, most of the disease-causing mutations described are
likely to be the consequence of non-homologous recombination or
gene conversion events [8,9]. In addition, about 130 rare point
mutations that arise independently of the pseudogene and that were
found specific to a population or a single family, have been
described to date (for details: http://www.hgmd.cf.ac.uk).
In the present work, we describe five novel CYP21A2 mutations
in patients from Argentina, diagnosed with 21-hydroxylase
deficiency. In addition, using a three-dimensional molecular
CYP21 model, the putative pathogenic mechanism of each
mutation was evaluated in silico. Our analysis revealed changes
in protein stability or in the surface charge of the mutant enzymes.
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All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from all patients and parents
involved in this study. The study was approved by the Ethic
Committee of the Instituto de Biologı ´a y Medicina Experimental,
Buenos Aires, Argentina.
Patients
Endocrine and genetic evaluation of patients were conducted at
the Division Endocrinologı ´a of the Hospital Durand and at the
Centro Nacional de Gene ´tica Me ´dica, Buenos Aires, Argentina.
Patients were included following the diagnostic criteria already
described [10,11]. Briefly, a clinical diagnosis of NC 21-
hydroxylase deficiency was established on the basis of late-onset
symptoms of androgen excess, elevated basal 17-hydroxyproges-
terone (17OH-P) (.2 ng/ml), and an abnormal -at least three-fold
the upper limit of normal- 60 minute 17OH-P response to
Synacten stimulation (.10 ng/ml). The SW form of the disease
was characterized by elevated 17OH-P concentrations and plasma
renin activity (.4,50 ng/ml/h), onset of hyperkalaemia, hypona-
traemia, dehydration and/or shock in the first month of life, with
the consequent requirement of mineralocorticoids and glucocor-
ticoids treatment. Females presented with ambiguous genitalia.
The SV form was diagnosed on the basis of elevated 17OH-P
levels and ambiguous genitalia in females, and no evidence of salt
wasting.
Details on clinical manifestations observed in patients in whom
novel mutations were found, are presented in Supporting
Information (Text S1).
Hormone assays
17-hydroxyprogesterone (17OHP), androstenedione (A4), tes-
tosterone (T) and dehydroepiandrosterone-sulphate (DHEA-S)
were assayed by radio-immunoassay (RIA) using a commercial kit
from Diagnostic System Laboratory (DSL), Houston, TX, USA.
Plasma Renin Activity (PRA) was measured using a commercial kit
from Renin, BioChem Immuno System, Rome, Italy (MAIAH), as
previously described [10,11].
DNA Analyses
Nucleotide numbering was performed following the guidelines
of the Human Genome Variation Society [12], using M13936.1
[13] as the genomic CYP21A2 reference sequence. All new data
has been deposited in the GeneBank database.
DNA was isolated from peripheral blood leucocytes and the 10
most frequent derived-pseudogene point mutations in the
CYP21A2 gene were screened, following methodology previously
established in our laboratory [10,11]. Briefly, CYP21A2 gene was
amplified by PCR in three overlapping fragments, and each
mutation was screened by allele-specific PCR or PCR-RFLP in a
second round of PCR using one of these previously amplified
fragments as templates.
Samples from patients with at least one non-determined allele
were further analyzed by direct sequencing. The entire coding and
proximal promoter regions of the CYP21A2 gene were specifically
amplified in four overlapping fragments using primers already
described [14–16]. Fragment 1 included the promoter region up to
exon 3, fragment 2 the region from exon 2 to exon 6, fragment 3
included the region from exon 3 to intron 7 and fragment 4 the
region from exon 6 to exon 10. PCR products were purified by
GFX PCR DNA and a Gel Band Purification Kit (GE Healthcare
Bio-Sciences, Cardiff, Wales, UK), following the Big Dye
terminator sequencing protocol (Applied Biosystems, Foster City,
CA, USA). Fluorescent samples were analyzed using an ABI prism
3730XL DNA sequencer.
Each fragment was sequenced at least twice (forward and
reverse orientation), and novel mutations were retested in at least
two independent PCRs. In addition, each mutation was further
analyzed by restriction enzyme digestion (see below). In order to
establish the segregation of mutated alleles, DNA from parents was
analyzed, when available. Alternatively, two independent allele-
specific PCR fragments were amplified using primers encompass-
ing the wild-type or the mutant p.V281L allele, in order to
determine if the novel mutation was located in trans with the
already identified mutation (patients 2 and 4). Each of these
fragments was further analyzed by direct sequencing.
In addition, 50 randomly selected subjects from the general
population were recruited and DNA samples were screened for the
novel mutations found in the patients. Briefly, CYP21A2 was
specifically amplified in two overlapping fragments (from the
promoter region to exon 6 and from exon 3 to exon 10,
respectively), and each mutation was further analyzed in a second
round of PCR. Screening of the g.782C.T mutation in exon 3
was performed by amplification of a 696-bp fragment from exon 3
to exon 6 with primers already described [14,15], followed by a
BtsCI restriction enzyme assay and a 2% Ethidium Bromide-
stained agarose gel electrophoresis. The wild type allele rendered
fragments of 77, 200 and 419 bp, while the mutant alleles showed
fragments of 200 and 496 bp. For the screening of mutations
g.940C.T in exon 4, g.1695A.G in exon 7 and the
g,2511_2512delGG in exon10, each exon was amplified with
primers already described [16], and PCR products were analyzed
by digestion with HhaI, Hin1II and BseDI restriction enzymes,
respectively. PCR product from exon 4 was electrophoresed in 2%
agarose gels stained with Ethidium bromide. The mutant allele
rendered one uncut fragment of 355 bp, while the wild type allele
rendered two fragments of 320 and 35 bp. Fragments from exon 7
and 10, were electrophoresed in 8% acrylamide-bisacrylamide gels
and silver-stained. The 274-bp fragment from exon 7 rendered
five fragments of 12, 27, 42, 72 and 121 bp in the wild-type alelle
and four fragments of 12, 27, 72, and 163 bp in the mutant one.
The 389-bp fragment from the wild-type alelle in exon 10
rendered fragments of 66, 77, 83 and 141 bp (along with
fragments of low molecular weight), while in the mutant allele,
fragments of 66, 83 and 218 bp were obtained. Mutation
g.2515G.A [17] was screened using primer 10F [16] and a
reverse mismatch one 59CCAGGCGCGCCAACCGCT39 (mis-
match base underlined). The 166-bp fragment was digested with
BsrbI restriction enzyme followed by 8% acrylamide-bisacryla-
mide gel electrophoresis and silver-stained. The mutant allele
remained uncut, while the wild-type allele rendered two fragments
of 150 and 16 bp.
Sequence analysis was performed using Blast-N algorithms. In
addition, similarities between different mammalian CYP21
proteins were assessed using Uniprot reference sequences and
the Clustal W multiple alignment program.
Modeling novel mutations
Semi-automatic homology modeling was carried out with Biskit
suite [18], which uses Modellerv91 as a modeling tool. Multiple
templates, ranging from 4 to 18, were used to generate the
different target models, having slightly better results using 18
templates. Table S1 presents all the templates used and its
corresponding identity to CYP21 protein in the aligned region.
The model that presented the best Modeller objective function
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analyses (model available upon request).
Once the best model was chosen, we used Foldx 3.0 beta (www.
foldx.crg.es) to generate point mutations and analyze changes in
protein stability. Since Foldx cannot deal with heme atoms,
mutations in residues that directly interact with the prostetic group
may be misleaded. Prior to any mutagenesis, the RepairPDB
FoldX command was used to optimize the total energy of the
protein. Mutagenesis was carried out using the BuildModel FoldX
command, and each mutation was repeated five times for each
structure. Protein stabilities were calculated using the Stability
command, and DG values were estimated as the difference
between the energy of the wild type protein and that of the mutant
enzyme. A threshold of 1,6 kcal/mol was considered, as it
corresponds to twice the standard deviation calculated with FoldX
and values above this threshold should significantly destabilize a
protein [19].
The five novel point mutations found in patients from our
cohort, together with 40 already described point mutations, were
also tested using a previously described 3D model (Protein Data
Bank ID:2GEG, [20]). Each mutation was performed five times
with both templates and the results were expressed as mean plus
standard deviations.
Results
Following an initial screening of the 10 most frequent
pseudogene-derived mutations, direct sequencing of the complete
coding and the proximal promoter regions was performed in those
patients with at least one non-determined allele. This combined
strategy revealed the presence of five novel mutations in four
NCCAH and one SW 21-hydroxylase-deficient patients from our
cohort. Representative electropherograms and restriction enzyme
digestion assays for the novel mutations are shown in Figure 1.
Table 1 summarizes the phenotypes, genotypes and biochemical
parameters of patients in whom new variants were found. None of
these mutations were found in 100 chromosomes of randomly
selected individuals from the general population.
In patient 1, due to the presence of g.782C.T mutation in exon
3, an arginine residue is replaced by a cysteine at position 132. In
patient 2, g.940C.T mutation located in exon 4 replaces an
arginine residue with a cysteine at position 149, and in patient 3,
g.1695A.G mutation in exon 7 leads to a change in residue M283
to V283. In addition, while g.2515G.A mutation in exon 10
evidenced in patient 4 replaces an aspartic acid with a lysine at
position 431, g.2511_2512delGG found in patient 5, leads to a
frameshift in the carboxy-terminal end of the protein. As shown in
Figure 2, all novel point mutations are located in CYP21 protein
residues that are conserved throughout mammalian species.
The putative pathogenic mechanisms of the novel variants were
analyzed in silico by a three-dimensional CYP21 structure
generated by homology modeling. Figure 3A shows a cartoon
scheme of the protein, highlighting the positions involved in point
mutations. In this work we used a structure-based approach and
the protein design algorithm FoldX to analyze these mutations and
to calculate changes in stability of CYP21A2 protein. Table 2
summarizes the results obtained for the predicted free energy
changes after amino acid substitution, using our model (Biskit,
[18]) and a previously described one (2GEG [20]). For
comparison, 40 mutations in which in vitro activities have been
already assayed were also analyzed (see Supporting Information:
Text S2, Table S2, Figure S1, Figure S2).
p.R132C (g.782C.T) mutation is located in the loop
connecting helixes C and D, and lies in a region involved in the
redox partner interaction [20]. Although this region is quite
different in both models (Figure S3), in both cases p.R132C
mutant disrupts favorable interactions between arginine and other
residues (R254, A126 and L127 for 2GEG model and P432
backbone for Biskit, data not shown). Since R132 is far from the
heme group and from other cysteine residues, no intra-protein
bond is expected for the C132 residue.
p.R149C (g.940C.T) mutation is predicted to destabilize the
protein in both models. C149 is close to C147, both are structured
on the same D alpha helix and oriented in opposite directions
(Figure S4). Consequently, no disulfide bridge is expected to be
formed. Since this position is partially exposed to the solvent and
away from the heme group, the putative effect on enzyme activity
could be related to protein destabilization.
p.M283V (g1695A.G) is very close to p.V281L mutation
(Figure 3B) in helix I, and it is also away from the heme group. In
contrast to p.V281L (Table S2), while our model predicts that this
mutation may stabilize the protein, a destabilization can be
expected by 2GEG model. These discordances could be related to
the differences found between both models in the predicted
structure for this region of the protein (Figure S3).
p.E431K (g.2515G.A) mutation lies at the beginning of L
helix and no protein destabilization is predicted (it marginally
stabilizes the protein by ,0.2 kcal/mol). Nevertheless, analyzing
the structure in detail, this residue is found exposed, and the
mutation involves a charge inversion from a negatively charged
glutamic acid to positively charged lysine. As shown in Figure 3C,
the p.E431K mutation significantly modifies the surface of the
protein, potentially affecting its interaction with ligands. Based on
molecular modeling, the effect of this mutation over protein
stability is probably independent of p.D322G mutation found on
the same allele. Both mutations are far away each other in the
protein structure and are oriented in opposite directions
(Figure 3A).
The frameshift g.2511_2512delGG mutation in exon 10
implies a huge change in the carboxy-terminal of the protein,
therefore it cannot be accurately modeled with the present
approach. Given that this mutation is located only one codon
apart from the heme-coordinating cysteine, introducing 26
aminoacids and leading to a complete different tract of 91
residues, a non-functional protein lacking the heme prostetic
group could be expected.
Discussion
The adrenocortical 21-hydroxylase is one of the key enzymes in
glucocorticoid and mineralocorticoid biosynthesis. Mutations in
the CYP21A2 gene have been reported in individuals affected with
CAH due to 21-hydroxylase deficiency. To date, a great number
of different mutations in the CYP21A2 gene have been described.
Most patients are compound heterozygotes, and their phenotype
depends on the underlying combination of mutations they present
[21]. Even though most patients carry CYP21A1P-derived
mutations, an increasing number of naturally occurring mutations
have been found in disease-causing alleles in the last years (see:
http://www.hgmd.cf.ac.uk for details). Most of them result in
amino acid substitutions that may disturb essential functional and/
or structural motifs of the protein.
In recent years, efforts have been made towards predicting
activities of mutant proteins. Given the practical impossibility to
solve every mutant structure, and in order to avoid expensive and
time-consuming in vitro activity assays, homology modeling
emerges as a useful tool to evaluate, through structure-based
methods, protein activity or stability impairment. Though this
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e15899Figure 1. Representative electropherograms (left panel) and restriction enzyme assays (right panel) of the five novel mutations
found. Left panel: A: Mutation g. 782C.T, in exon 3, changes an R residue to C at position 132. B: Mutation g.940C.T, in exon 4, changes an R
residue in position 149 to a C residue. C. Mutation g.1695A.G, in exon 7, predicts a change in residue M283 to V283. D: mutation g.2515G.A, in
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template in order to be reliable.
Given an adequate structure template, the FoldX algorithm
allows the prediction of an eventual protein destabilization that, at
the same time, can be correlated to a decrease in protein activity.
When the mutation affects the active site, more sophisticated and
time-consuming Quantum Mechanical computational techniques
should be used. Structure-based energetic analysis has been
successfully applied to the study of phenylketonuria [22], where a
very good correlation between predicted and experimental protein
stability – key factor in protein function- has been obtained.
In the present work, we describe five novel mutations found in
21-hydroxylase-deficient patients from our cohort. Considering
that none of these mutations were found in the control individuals
analyzed, and given the fact that all five mutations are located in
CYP21 protein residues fully conserved throughout mammalian
species, an impairment of 21-hydroxylase enzyme activity may
consequently be suggested.
The putative pathogenic mechanisms of these newly described
mutations were analyzed in silico, by means of mutagenesis
modeling and protein stability calculations using our own
generated model, as well as a previously available one. It should
be noted that the quality and accuracy of predictions using the
FoldX force field crucially depend on the availability of high
resolution structures, usually determined by X-ray crystallography.
In the case of P450CYP21A2, we are dealing with two main
limitations: the lack of a high resolution protein structure, and the
impossibility to evaluate the energetic of mutations affecting heme-
interacting residues. Nevertheless, the use of approximate models
allows to make some predictions with certain accuracy, and the
development of a pipeline to be applied when the structure of the
CYP21 protein becomes available.
In view of previous observations that demonstrated a correlation
between the predicted protein stability and the severity of CAH
[20], in the present work we also analyzed mutations with known
in vitro enzymatic activity and compared our results with those
obtained with the model proposed by Robins et al to further
validate our findings. Considering only those regions that are well-
conserved and similarly structured by both models, it is expected
that in one third of the protein (mostly in the alpha helix)
mutations could be evaluated accurately. An approximate
evaluation can be carried out in another third of the protein.
Little can be inferred about the remaining third, which is
composed of heme-interacting residues and regions with diverging
conformations between different models, thus suggesting that
predictions in these regions of the protein may not be reliable.
Indeed, we found a good correlation between experimental
activity and predicted free energy when those mutants not likely
to be involved in interaction with ligands were analyzed. In view of
the different techniques employed to obtain both models, this
convergence in the results may suggest that predictions for
mutations in these regions of the protein may be consistent.
It is important to note that protein stability but not protein
activity can be evaluated with this approach. In general, it is
expected that a decrease in stability will affect activity; neverthe-
less, the opposite scenario may not be true. Such is the case of
p.V281L mutation, for example, for which although both models
predicted a stabilizing energy, previous in vitro analyses had
demonstrated a decreased enzymatic activity [23,24]. It should be
highlighted, however, that in some cases where no stability
impairment is found, the disease-causing effect could be explained
by amino acid residues affecting other functions, e.g. heme
coordination, post-translational modifications motif, interface with
other interacting proteins or ligands.
After the initial analysis of mutations with known in vitro
enzymatic activity, we further analyzed the novel mutations herein
described using both models in parallel. Even though the region
surrounding p.R132C mutation appears quite different in one
model as compared to the other one, in both cases the C132
mutant disrupts favorable interactions. R132 is part of a cluster of
basic amino acids suggested to be involved in the redox partner
interaction with P450 Oxido Reductase (POR) [20]. Since
mutations in these basic amino acids are likely to cause
electrostatic disturbances, an impairment of the enzyme biological
activity by C132 mutation would be expected. Nevertheless, the
magnitude of this impairment can not be predicted. Robins et al.
[20] developed a model used to describe single missense mutations
and their predictive activities (http://bioinfo6.limbo.ifm.liu.se/
Table 1. Phenotype, genotype and hormonal values in the five patients in whom novel mutations were found.
Patient Phenotype Gender Genotype 17-OHP (basal) 17-OHP (stimulated) D4A To DHEA-S
1N C F p.R132C/N 5.7 30 ND 0.6 3430
2 NC F p.V281L/p.R149C 8.5 34 5.2 0.55 2860
3 NC F IV2-13 A/C.G/p.M283V
a 19 ND 6.3 1.4 1500
4 NC F p.V281L/p.D322G-p.E431K 23 ND 4.8 1.2 1800
5* SW F g.2511_2512delGG/
p.I172N
b
10 ND 12.4 1.64 1802
Novel mutations are displayed in bold and hormonal values are expressed in ng/ml. Values of basal 17 hydroxyprogesterone (17-OHP) and after ACTH stimulation, basal
androstenedione (D4A), testosterone (To) and dehydroepiandrosterone sulphate (DHEA-S) are showed. *Hormonal values under treatment with 6 mg meprednisone
plus 0.05 mg 9a-fluorocortisol.
a: cis/trans presence of mutations is assumed.
b: maternal/paternal alleles.
ND: not determined. N: Normal wild type allele.
doi:10.1371/journal.pone.0015899.t001
exon 10, changes E431 to K431. E: mutation g.2511_2512delGG in exon 10 leads to a frameshift in the carboxy-terminal end of the protein. Right
panel: A: BtsCI restriction enzyme assay for R132C. B: HhaI restriction enzyme assay for R149C. C: Hin1II restriction enzyme assay for M283V. D: BseDI
restriction enzyme assay for g.2511_2512delGG in exon 10. E: BsrbI restriction enzyme assay for E431K. C: control individuals, P: patients. C(-E): control
without enzyme. MWM: molecular weight marker.
doi:10.1371/journal.pone.0015899.g001
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posed could represent an oversimplified outcome since it is based
on a low-identity homology model. When dealing with proteins
with no high resolution structure available, a trained eye may be
necessary in order to draw meaningful conclusions. This is
particularly important in cases in which multiple mutations are
present and a cooperative effect needs to be evaluated.
It should be noted that under some circumstances the nature of
the mutation present on the homologous allele together with the
phenotype of the patient could contribute to predict the residual
enzymatic activity disclosed by the novel mutation. However, in
the case of patient 1, this putative assumption is not possible due to
the lack of demonstrable mutation on the second allele. Though
the entire gene and promoter regions were sequenced, no
additional mutations were found. No variations were either found
when we analyzed, by direct sequencing, two previously described
regulatory regions [25,26] (data not shown). The absence of
mutations in patients diagnosed with 21-hydroxylase deficiency
has been described previously [27–33].
R149 residue, which lies in the D helix, may not be involved in
known interactions with other proteins or cofactors. When
modeling the protein with the C149 residue, no apparent partner
to form a disulfide bridge can be predicted. Given the fact that
both models suggest a significant destabilization for pR149C, we
proposed that a change in the stability of the protein may be
responsible for protein missfunction.
Residue M283 is located in the well-conserved helix I, which is
suggested to be involved both in heme binding and in substrate
recognition [20]. As we have already pointed out, both models
disclosed different results for p.M283V mutation. While the 2GEG
model showed no differences between the mutant and the wild-
type protein in the free energy elicited, a huge difference in protein
stability is predicted in our model. These discordances could
suggest that none of the models may actually represent a good
Figure 2: Partial Clustal W alignment analyses of CYP21A2 proteins from different mammalian species. The residues of each mutation
are highlighted in yellow. A: R residue at position 132. B: R residue at position 149. C. M residue at position 283. D: E residue at position 431.
doi:10.1371/journal.pone.0015899.g002
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to p.V281L, the putative pathogenic mechanism of p.M283V
mutation should be similar to that previously proposed for the
former, as the impaired enzyme activity could be related to
alterations in ligand recognition/migration or in protein-protein
interactions [21]. Considering the in vitro activity of 281L, close to
30-50% [23,24], and the almost null residual enzymatic activity of
the protein codified by the homologous allele in this patient, we
suggest that 283V may be associated with a mild phenotype.
Interestingly, another point mutation at the same position, 283L,
has previously been associated with the NC form of the disease
[31].
Both models predicted no destabilization of the protein for the
p.E431K mutation. It should be noted, however, that E431 lies
within a cluster of basic residues located on the surface of the redox
partner binding site of CYP21 [34]. Therefore, changes in the
electrostatic potential in this surface, in our case adding an
additional basic amino acid residue instead of an acidic one, could
contribute to a miss-interaction with POR. Replacement of a
glutamic acid by a basic lysine may affect the correct orientation of
the ligands by disruptingthe surface chargepatternor by enhancing
the interaction energy in an already highly basic-residue dense
region, thus potentially affecting enzyme dissociation.
p.E431K mutation was found to be located in cis with a
previously described p.D322G (g.2012A.G) mutation [35]. Since
functional in vitro studies have demonstrated that p.D322G impairs
the activity of the enzyme [36], we cannot rule out that the
pathological consequence for this allele might indeed rely on that
mutation. Nevertheless, a significant difference in the final
enzymatic activity has been reported when more than one mild
mutation lies on the same allele [37–40]. Given the fact that the
molecular modeling herein described revealed probably indepen-
dent effects of these mutations over protein stability, in vitro
analyses seem necessary to further clarify the severity of this allele,
for future appropriate genetic counseling.
Presence of the g.2511_2512delGG frameshift mutation in
patient 5 introduces a complete new carboxy-terminal sequence to
the protein. Although the protein is translated accurately up to the
heme-coordinating cysteine at position 428, the new protein
domain probably prevents the correct interaction with the heme
group, thus rendering the protein enzymatically inactive. Notably,
while the presence of the p.I172N mutation on the homologous
allele may predict a SV form of the disease, the phenotype of the
patient herein reported is consistent with a SW form of the disease.
Similarly to patient 1, after analyzing the entire gene, promoter
and regulatory regions, no additional mutations were found that
could explain the lack of phenotype/genotype correlation. A
frameshift mutation at the carboxy-terminal domain of the protein
in nucleotide 2672 has been previously described [32,41]. This
frameshift mutation also predicted a new amino acid tract of 45
residues, but no phenotype/genotype discrepancy was found for
the SV patient reported [32]. Considering that it has been
suggested that the enzymatic residual activity of the p.I172N
mutation is not always enough to prevent salt wasting [27], these
observations as a whole might imply that other genetic and/or
Figure 3: Structural analysis. A: Cartoon representation of the structure of CYP21A2. Residues implicated in the novel mutations found are
labeled and highlighted by blue spheres. The residue D322 is also represented. Heme cofactor is depicted in sticks. B: Model discrepancies in the
surroundings of V281. Detail of the superimposition of the Biskit (green) and 2GEG (orange) models. V281 and M283 are named and depicted in
sticks. C: Enhancement of the basic region in the mutant surface. Surface electrostatics of the wild type E431 and mutant K431 are presented. Acidic
regions are depicted in red and basic ones in blue.
doi:10.1371/journal.pone.0015899.g003
Table 2. Stability effects for the different point mutations
found.
Biskit 2GEG
p.R132C 0.160.06 4.1360.08
p.R149C 1.8860.18 1.6860.32
p.M283V 23.7760.40 1.6960.05
p.E431K 20.2060.17 20.3760.10
Changes in DG caused by mutations were evaluated by FoldX for our model
(Biskit) as well as for a previously described one (2GEG). Values are expressed as
kcal mol
-1 with their corresponding standard deviation.
doi:10.1371/journal.pone.0015899.t002
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the enzyme in vivo. In addition, the possibility that the newly
generated carboxi-terminal domain could in fact act as a negative
dominant protein should also be considered. It might be
hypothesized that the mutated protein could be folded in a way
which may allow it to quench natural ligands and/or to disrupt
protein networks inside the cell, dramatically impairing the
function of the protein synthesized by the homologous allele. In
the near future, in vitro studies should be conducted -including co-
expression with different mutant alleles- to further analyze the
biological implication of the g.2511_2512delGG mutation.
In conclusion, we herein describe five novel mutations found in
21-hydroxylase-deficient patients from the Argentinean popula-
tion. All novel mutations are located in CYP21 protein residues
fully conserved throughout mammalian species. In all cases,
molecular modeling revealed changes in the stability and/or
surface charge of the protein that could be related to the clinical
manifestation found in patients.
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